Drug Profile
FF 10502
Alternative Names: FF-10502-01Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator FUJIFILM Holdings Corporation
- Developer Strategia Therapeutics
- Class Antineoplastics; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
Most Recent Events
- 15 Feb 2022 FF 10502 is still in phase I/II trials for Solid tumours and Lymphoma in USA (FUJIFILM pipeline, February 2022)
- 05 Nov 2020 FUJIFILM Holdings Corporation completes a phase I/II trial in Lymphoma (Late-stage disease) and Solid Tumors (Late-stage disease) in the USA (IV) (NCT02661542)
- 03 Jun 2019 Updated efficacy and adverse events data from a phase I trial in Lymphoma and Solid tumours (Late-stage disease) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)